A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

about

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).

P2860

Q55451692-8A0F88D9-4A9D-4DB8-A375-5D39B1D283DD

P2860

A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

Item

http://www.wikidata.org/entity/Q41385777

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase II study of arsenic tr ...... refractory malignant lymphoma.

@en

type

Item

label

A phase II study of arsenic tr ...... refractory malignant lymphoma.

@en

prefLabel

A phase II study of arsenic tr ...... refractory malignant lymphoma.

@en

P1476

A phase II study of arsenic tr ...... refractory malignant lymphoma.

@en

P2093

Desheng Kong

http://www.w3.org/2001/XMLSchema#string

Guoxun Sun

http://www.w3.org/2001/XMLSchema#string

Hongli Zhao

http://www.w3.org/2001/XMLSchema#string

Luojia Hong

http://www.w3.org/2001/XMLSchema#string

Mingming Zhao

http://www.w3.org/2001/XMLSchema#string

Wudan Shi

http://www.w3.org/2001/XMLSchema#string

Yujing Zhang

http://www.w3.org/2001/XMLSchema#string

Zhenkui Qiao

http://www.w3.org/2001/XMLSchema#string

P2860

Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.

Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.

Management of relapsed-refractory diffuse large B cell lymphoma.

P2888

s12032-015-0526-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-015-0526-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014068409

http://www.w3.org/2001/XMLSchema#string

P698

25698531

http://www.w3.org/2001/XMLSchema#string

A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

about

P2860

P2860

A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698